WO2009070767A3 - Systemic instigation systems to study tumor growth or metastasis - Google Patents

Systemic instigation systems to study tumor growth or metastasis Download PDF

Info

Publication number
WO2009070767A3
WO2009070767A3 PCT/US2008/085040 US2008085040W WO2009070767A3 WO 2009070767 A3 WO2009070767 A3 WO 2009070767A3 US 2008085040 W US2008085040 W US 2008085040W WO 2009070767 A3 WO2009070767 A3 WO 2009070767A3
Authority
WO
WIPO (PCT)
Prior art keywords
metastasis
tumor
systems
growth
tumor growth
Prior art date
Application number
PCT/US2008/085040
Other languages
French (fr)
Other versions
WO2009070767A2 (en
Inventor
Sandra S. Mcallister
Robert A. Weinberg
Original Assignee
Whitehead Institute For Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Institute For Biomedical Research filed Critical Whitehead Institute For Biomedical Research
Publication of WO2009070767A2 publication Critical patent/WO2009070767A2/en
Publication of WO2009070767A3 publication Critical patent/WO2009070767A3/en
Priority to US12/745,221 priority Critical patent/US20110206614A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides tumor instigation systems that can be used to characterize tumor growth and/or metastasis. In some embodiments, the present invention provides a method for studying tumor outgrowth or metastasis including the steps of: (a) providing an animal host; (b) introducing into the animal host one or more cells that instigate the growth of an otherwise indolent tumor; (c) introducing into the animal host a tumor; wherein the presence of the one or more cells or a progeny thereof in the animal host enhances the growth and/or metastasis of the tumor. Among other things, the inventive methods and systems in accordance with the present invention can be used to identify modulators and/or contributors of tumor growth or metastasis, as well as diagnostic and/or therapeutic agents for use in monitoring and/or modulating tumor growth and/or metastasis.
PCT/US2008/085040 2007-11-23 2008-12-18 Systemic instigation systems to study tumor growth or metastasis WO2009070767A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/745,221 US20110206614A1 (en) 2007-11-23 2010-11-26 Systemic instigation systems to study tumor growth or metastasis

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US470407P 2007-11-28 2007-11-28
US61/004,704 2007-11-28
US6391608P 2008-02-06 2008-02-06
US61/063,916 2008-02-06
US6077408P 2008-06-11 2008-06-11
US61/060,774 2008-06-11

Publications (2)

Publication Number Publication Date
WO2009070767A2 WO2009070767A2 (en) 2009-06-04
WO2009070767A3 true WO2009070767A3 (en) 2009-10-22

Family

ID=40679227

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/085040 WO2009070767A2 (en) 2007-11-23 2008-12-18 Systemic instigation systems to study tumor growth or metastasis

Country Status (1)

Country Link
WO (1) WO2009070767A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US8795970B2 (en) 2008-11-07 2014-08-05 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
US9043160B1 (en) 2009-11-09 2015-05-26 Sequenta, Inc. Method of determining clonotypes and clonotype profiles
US9150905B2 (en) 2012-05-08 2015-10-06 Adaptive Biotechnologies Corporation Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions
US9181590B2 (en) 2011-10-21 2015-11-10 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
US9512487B2 (en) 2008-11-07 2016-12-06 Adaptive Biotechnologies Corp. Monitoring health and disease status using clonotype profiles

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US8691510B2 (en) 2008-11-07 2014-04-08 Sequenta, Inc. Sequence analysis of complex amplicons
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
EP2370091B1 (en) 2008-12-05 2017-04-12 Whitehead Institute for Biomedical Research Compositions and methods relating to mir-31
WO2010083456A1 (en) 2009-01-15 2010-07-22 Imdaptive Inc. Adaptive immunity profiling and methods for generation of monoclonal antibodies
SG176691A1 (en) 2009-06-25 2012-01-30 Hutchinson Fred Cancer Res Method of measuring adaptive immunity
EP3556870B9 (en) 2010-07-27 2022-09-28 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
EP2689787A1 (en) 2010-09-03 2014-01-29 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
SA112330278B1 (en) 2011-02-18 2015-10-09 ستيم سينتركس، انك. Novel modulators and methods of use
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
AU2012347460B2 (en) 2011-12-09 2017-05-25 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
JP6302847B2 (en) 2012-03-05 2018-03-28 アダプティヴ バイオテクノロジーズ コーポレーション Determination of paired immunoreceptor chains from frequency matched subunits
JP6449160B2 (en) 2012-10-01 2019-01-09 アダプティブ バイオテクノロジーズ コーポレイション Cross-reference of applications related to immune competence assessment by adaptive immune receptor diversity and clonal characterization
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
EP3114240B1 (en) 2014-03-05 2019-07-24 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
ES2777529T3 (en) 2014-04-17 2020-08-05 Adaptive Biotechnologies Corp Quantification of adaptive immune cell genomes in a complex mixture of cells
PL3137114T3 (en) 2014-04-30 2021-06-28 Pfizer Inc. Anti-ptk7 antibody-drug conjugates
SG11201608415QA (en) * 2014-04-30 2016-11-29 Max Delbrück Ct Für Molekulare Medizin In Der Helmholtz Gemeinschaft Humanized antibodies against cd269 (bcma)
EP3715455A1 (en) 2014-10-29 2020-09-30 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
CA2968543C (en) 2014-11-25 2024-04-02 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
ES2858306T3 (en) 2015-02-24 2021-09-30 Adaptive Biotechnologies Corp Method for determining HLA status by sequencing the immune repertoire
EP3277294B1 (en) 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
CA3083949A1 (en) * 2017-11-30 2020-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040016011A1 (en) * 2002-05-17 2004-01-22 Beijing Institute Of Biotechnology Mouse model for inducing hepatocellular carcinoma by targeted integration of hepatitis B virus genes
WO2007041364A2 (en) * 2005-09-30 2007-04-12 Government Of The United States Of America, As Represented By The Secretary Conjugates for modulating the immune tolerance
US20070148766A1 (en) * 2003-11-04 2007-06-28 Biomaster, Inc. Method and system for preparing stem cells from fat tissue

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040016011A1 (en) * 2002-05-17 2004-01-22 Beijing Institute Of Biotechnology Mouse model for inducing hepatocellular carcinoma by targeted integration of hepatitis B virus genes
US20070148766A1 (en) * 2003-11-04 2007-06-28 Biomaster, Inc. Method and system for preparing stem cells from fat tissue
WO2007041364A2 (en) * 2005-09-30 2007-04-12 Government Of The United States Of America, As Represented By The Secretary Conjugates for modulating the immune tolerance

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US9416420B2 (en) 2008-11-07 2016-08-16 Adaptive Biotechnologies Corp. Monitoring health and disease status using clonotype profiles
US9523129B2 (en) 2008-11-07 2016-12-20 Adaptive Biotechnologies Corp. Sequence analysis of complex amplicons
US9512487B2 (en) 2008-11-07 2016-12-06 Adaptive Biotechnologies Corp. Monitoring health and disease status using clonotype profiles
US9217176B2 (en) 2008-11-07 2015-12-22 Sequenta, Llc Methods of monitoring conditions by sequence analysis
US8795970B2 (en) 2008-11-07 2014-08-05 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
US9347099B2 (en) 2008-11-07 2016-05-24 Adaptive Biotechnologies Corp. Single cell analysis by polymerase cycling assembly
US9228232B2 (en) 2008-11-07 2016-01-05 Sequenta, LLC. Methods of monitoring conditions by sequence analysis
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9043160B1 (en) 2009-11-09 2015-05-26 Sequenta, Inc. Method of determining clonotypes and clonotype profiles
US9181590B2 (en) 2011-10-21 2015-11-10 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
US9279159B2 (en) 2011-10-21 2016-03-08 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
US9371558B2 (en) 2012-05-08 2016-06-21 Adaptive Biotechnologies Corp. Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions
US9150905B2 (en) 2012-05-08 2015-10-06 Adaptive Biotechnologies Corporation Compositions and method for measuring and calibrating amplification bias in multiplexed PCR reactions

Also Published As

Publication number Publication date
WO2009070767A2 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
WO2009070767A3 (en) Systemic instigation systems to study tumor growth or metastasis
WO2010031056A3 (en) Methods and compositions for modulating ire1, src, and abl activity
WO2008118392A3 (en) Synthetic cell platforms and methods of use thereof
WO2010030963A3 (en) Modulation of bcl11a for treatment of hemoglobinopathies
WO2009092087A3 (en) Selective differentiation, identification, and modulation of human th17 cells
WO2009123762A3 (en) Method of screening single cells for the production of biologically active agents
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
SG170826A1 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
WO2012122050A3 (en) Systems, devices, and methods for enviromental monitoring in agriculture
GB2467467B (en) TAZ/WWTR1 for diagnosis and treatment of cancer
WO2009086427A8 (en) Systems and methods for workflow processing
WO2006137941A3 (en) Methods and compositions involving mirna and mirna inhibitor molecules
NZ591137A (en) Methods and systems for predicting response of cells to a therapeutic agent
WO2010009000A8 (en) Strip connectors for measurement devices
WO2007047408A3 (en) Promac signature application
WO2008091814A3 (en) Assessment of asthma and allergen-dependent gene expression
NZ609824A (en) Immunochromatography devices, methods and kits
MX366369B (en) Method for a cell-based drug screening assay and the use thereof.
WO2012024546A3 (en) Incorporation of health measurments in analysis and interpretation of functional biological response data
WO2012083274A3 (en) Methods for diagnosis, prognosis and methods of treatment
WO2009022988A3 (en) Vhz for diagnosis and treatment of cancer
DE602008005172D1 (en) MARKING-FREE SINGLE CELL TEST
WO2012015249A3 (en) Method for screening diabetes treating agent
WO2008132861A1 (en) Culture container, method for culturing cells or tissues and method for analyzing cells or tissues
WO2014146035A3 (en) Compositions and methods for cancer diagnosis

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08854537

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08854537

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12745221

Country of ref document: US